Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate plus prednisone with or without abemaciclib in metastatic castration-resistant prostate cancer
jRCT2041210106Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Abemaciclib + abiraterone acetate + prednisone with Placebo + abiraterone acetate + prednisone (2 arms). Primary endpoint: Radiographic progression-free survival (rPFS) by investigator assessment. Started Oct 2021; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2041210106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210106.